JP2019105645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019105645A5
JP2019105645A5 JP2019026401A JP2019026401A JP2019105645A5 JP 2019105645 A5 JP2019105645 A5 JP 2019105645A5 JP 2019026401 A JP2019026401 A JP 2019026401A JP 2019026401 A JP2019026401 A JP 2019026401A JP 2019105645 A5 JP2019105645 A5 JP 2019105645A5
Authority
JP
Japan
Prior art keywords
time point
subject
level
macers
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019026401A
Other languages
English (en)
Japanese (ja)
Other versions
JP6788050B2 (ja
JP2019105645A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019105645A publication Critical patent/JP2019105645A/ja
Publication of JP2019105645A5 publication Critical patent/JP2019105645A5/ja
Application granted granted Critical
Publication of JP6788050B2 publication Critical patent/JP6788050B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019026401A 2008-04-18 2019-02-18 主要有害心イベントのリスクを予測する方法 Expired - Fee Related JP6788050B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4615808P 2008-04-18 2008-04-18
US61/046,158 2008-04-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017162932A Division JP6484679B2 (ja) 2008-04-18 2017-08-28 主要有害心イベントのリスクを予測する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020181010A Division JP2021039108A (ja) 2008-04-18 2020-10-29 主要有害心イベントのリスクを予測する方法

Publications (3)

Publication Number Publication Date
JP2019105645A JP2019105645A (ja) 2019-06-27
JP2019105645A5 true JP2019105645A5 (enExample) 2019-10-24
JP6788050B2 JP6788050B2 (ja) 2020-11-18

Family

ID=41199760

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011505224A Expired - Fee Related JP5526122B2 (ja) 2008-04-18 2009-04-17 主要有害心イベントのリスクを予測する方法
JP2014082442A Expired - Fee Related JP5873521B2 (ja) 2008-04-18 2014-04-14 主要有害心イベントのリスクを予測する方法
JP2016006007A Expired - Fee Related JP6200975B2 (ja) 2008-04-18 2016-01-15 主要有害心イベントのリスクを予測する方法
JP2017162932A Expired - Fee Related JP6484679B2 (ja) 2008-04-18 2017-08-28 主要有害心イベントのリスクを予測する方法
JP2019026401A Expired - Fee Related JP6788050B2 (ja) 2008-04-18 2019-02-18 主要有害心イベントのリスクを予測する方法
JP2020181010A Ceased JP2021039108A (ja) 2008-04-18 2020-10-29 主要有害心イベントのリスクを予測する方法

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2011505224A Expired - Fee Related JP5526122B2 (ja) 2008-04-18 2009-04-17 主要有害心イベントのリスクを予測する方法
JP2014082442A Expired - Fee Related JP5873521B2 (ja) 2008-04-18 2014-04-14 主要有害心イベントのリスクを予測する方法
JP2016006007A Expired - Fee Related JP6200975B2 (ja) 2008-04-18 2016-01-15 主要有害心イベントのリスクを予測する方法
JP2017162932A Expired - Fee Related JP6484679B2 (ja) 2008-04-18 2017-08-28 主要有害心イベントのリスクを予測する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020181010A Ceased JP2021039108A (ja) 2008-04-18 2020-10-29 主要有害心イベントのリスクを予測する方法

Country Status (13)

Country Link
US (5) US8090562B2 (enExample)
EP (5) EP3093663B1 (enExample)
JP (6) JP5526122B2 (enExample)
AU (3) AU2009236109B2 (enExample)
CA (1) CA2720674A1 (enExample)
DK (4) DK3093663T3 (enExample)
ES (4) ES2443125T3 (enExample)
HR (2) HRP20131100T1 (enExample)
HU (2) HUE039963T2 (enExample)
PL (4) PL2660599T3 (enExample)
PT (4) PT2827152T (enExample)
SI (4) SI2827152T1 (enExample)
WO (1) WO2009129454A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
ES2573471T3 (es) 2002-05-09 2016-06-08 The Brigham And Women's Hospital, Inc. 1L1RL-1 como un marcador de enfermedades cardiovasculares
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
EP2021799B1 (en) * 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
EP2995951B1 (en) * 2006-05-02 2019-02-13 Critical Care Diagnostics, Inc. Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
US9968266B2 (en) 2006-12-27 2018-05-15 Cardiac Pacemakers, Inc. Risk stratification based heart failure detection algorithm
PT2827152T (pt) * 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
JP5711131B2 (ja) * 2008-10-07 2015-04-30 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最初の有害事象の予測のためのバイオマーカー
US9561006B2 (en) * 2008-10-15 2017-02-07 The United States Of America As Represented By The Secretary Of The Navy Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival
US8417541B1 (en) * 2009-08-27 2013-04-09 Cerner Innovation, Inc. Multi-stage model for predicting probabilities of mortality in adult critically ill patients
EP2480129B1 (en) * 2009-09-25 2019-11-06 Volcano Corporation Device for determining the likelihood of a patient having a clinically silent event based on ascertained physiological parameters
HRP20160461T1 (hr) 2010-04-09 2016-06-17 Critical Care Diagnostics, Inc. Solubilna humana st-2 antitijela i eseji
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
EP2734222B1 (en) 2011-07-18 2016-10-19 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
MX357740B (es) 2012-05-18 2018-07-23 Critical Care Diagnostics Inc Métodos para determinar el pronóstico del tratamiento de un sujeto con un desfibrilador cardíaco implantado, un dispositivo de tratamiento de resincronización cardíaca o un dispositivo combinado de desfibrilador cardíaco implantado y de resincronización cardíaca.
CN102830234A (zh) * 2012-08-10 2012-12-19 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
PL2885641T3 (pl) 2012-08-16 2018-04-30 Critical Care Diagnostics, Inc. Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi
MX375520B (es) * 2012-08-21 2025-03-06 Critical Care Diagnostics Inc Estratificación de riesgo para marcador múltiple.
RU2510505C1 (ru) * 2012-11-15 2014-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда
GB201310290D0 (en) * 2013-06-10 2013-07-24 Univ Manchester Method for determining a probability of a major adverse cardiac event (MACE)
MX2016009060A (es) * 2014-01-10 2016-09-09 Critical Care Diagnostics Inc Metodos y sistemas para determinar el riesgo de falla cardiaca.
WO2016048388A1 (en) 2014-09-26 2016-03-31 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
WO2016140958A1 (en) * 2015-03-02 2016-09-09 Estes Edward Harvey Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score
CN109152529B (zh) 2016-04-01 2021-10-22 心脏起搏器股份公司 多疾病患者管理
AT518560B1 (de) * 2016-04-18 2018-01-15 Trumpf Maschinen Austria Gmbh & Co Kg Biegebalken für eine Schwenkbiegemaschine
WO2018200470A1 (en) 2017-04-29 2018-11-01 Cardiac Pacemakers, Inc. Heart failure event rate assessment
US20200074313A1 (en) * 2018-08-29 2020-03-05 Koninklijke Philips N.V. Determining features to be included in a risk assessment instrument
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
MX2021014015A (es) 2019-05-17 2022-02-21 Regeneron Pharma Metodos basados en el genoma para reducir el riesgo cardiovascular.
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
CN117099000A (zh) * 2021-03-08 2023-11-21 赛诺菲 心血管疾病
WO2023086746A1 (en) * 2021-11-11 2023-05-19 Beckman Coulter, Inc. Assessment of risk for major adverse cardiac event

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 hBNPのC端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトst2をコードするdna、該dnaの発現産物、該dnaを発現させることによる発現産物の製造方法
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスst2lをコードするdna、該dnaの発現産物、該dnaを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
CA2263832A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
EP0981619A1 (en) 1997-02-28 2000-03-01 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
PT1493439E (pt) 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
ATE489633T1 (de) 1997-06-10 2010-12-15 Lpath Inc Verfahren zum frühzeitigen nachweis herzerkrankungen
JP3516655B2 (ja) 1997-09-11 2004-04-05 塩野義製薬株式会社 Bnpの免疫測定法
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
EP1140137A2 (en) 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6677356B1 (en) 1999-08-24 2004-01-13 Medicure International Inc. Treatment of cardiovascular and related pathologies
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
BR0107157A (pt) 2000-08-22 2002-07-16 Brigham And Womens Hospital In Diagnose e tratamento de condições cardiovasculares
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019L (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE60233301D1 (de) 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
ES2573471T3 (es) 2002-05-09 2016-06-08 The Brigham And Women's Hospital, Inc. 1L1RL-1 como un marcador de enfermedades cardiovasculares
US20040005615A1 (en) 2002-05-24 2004-01-08 Jing Li Amplification and overexpression of oncogenes
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
EP1565753A2 (en) * 2002-11-21 2005-08-24 The University Of Leicester Bodily fluid markers of tissue hypoxia
AU2003299441A1 (en) 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050250156A1 (en) 2003-10-31 2005-11-10 Shebuski Ronald J Detection of acute myocardial infarction biomarkers
CA3050151C (en) 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
WO2006066095A1 (en) 2004-12-17 2006-06-22 Clearwater Systems Corporation Method and apparatus for treating fluids
ES2316044T3 (es) 2005-01-24 2009-04-01 F. Hoffmann-La Roche Ag El uso de hormonas cardiacas para evaluar un riesgo cardiovascular con respecto a la administracion de farmacos antiinflamatorios.
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのadamts13の測定と利用
ATE476657T1 (de) * 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
EP2021799B1 (en) 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) * 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
EP2995951B1 (en) 2006-05-02 2019-02-13 Critical Care Diagnostics, Inc. Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
EP2924440A3 (en) * 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
US20080233191A1 (en) 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
JP2010526555A (ja) 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
US20100267062A1 (en) 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
PT2827152T (pt) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
WO2010025393A2 (en) * 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
WO2010054810A1 (en) 2008-11-11 2010-05-20 B.R.A.H.M.S Ag Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
KR20120101064A (ko) 2009-11-13 2012-09-12 비쥐 메디신, 인코포레이티드 심근 경색의 위험 인자 및 예측
US8258456B2 (en) 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
HRP20160461T1 (hr) 2010-04-09 2016-06-17 Critical Care Diagnostics, Inc. Solubilna humana st-2 antitijela i eseji
RU2618437C2 (ru) 2010-11-01 2017-05-03 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
US8615387B2 (en) * 2011-04-07 2013-12-24 Invensys Systems, Inc. Dynamic simulation of fluid filled vessels
EP2734222B1 (en) 2011-07-18 2016-10-19 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
MX357740B (es) 2012-05-18 2018-07-23 Critical Care Diagnostics Inc Métodos para determinar el pronóstico del tratamiento de un sujeto con un desfibrilador cardíaco implantado, un dispositivo de tratamiento de resincronización cardíaca o un dispositivo combinado de desfibrilador cardíaco implantado y de resincronización cardíaca.
PL2885641T3 (pl) * 2012-08-16 2018-04-30 Critical Care Diagnostics, Inc. Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi
MX375520B (es) 2012-08-21 2025-03-06 Critical Care Diagnostics Inc Estratificación de riesgo para marcador múltiple.
US9665593B2 (en) * 2013-03-28 2017-05-30 International Business Machines Corporation Dynamically synching elements in file
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
MX2016009060A (es) 2014-01-10 2016-09-09 Critical Care Diagnostics Inc Metodos y sistemas para determinar el riesgo de falla cardiaca.
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Similar Documents

Publication Publication Date Title
JP2019105645A5 (enExample)
US11340236B2 (en) Methods for treating or predicting risk of a ventricular tachyarrhythmia event
JP6757757B2 (ja) 高血圧症を発症するリスクを予測するための方法
JP2011520098A5 (enExample)
Adamopoulos et al. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy
HRP20131100T1 (hr) Predviđanje rizika većih štetnih srčanih slučajeva
Schindler et al. Exercise in heart failure—what is the optimal dose to improve pathophysiology and exercise capacity?
Antoncecchi et al. High prevalence of cardiac post-acute sequelae in patients recovered from Covid-19. Results from the ARCA post-COVID study
Wu et al. Elevated plasma adiponectin levels are associated with abnormal corrected QT interval in patients with stable angina
RU2785311C1 (ru) Способ прогнозирования неблагоприятных кардиоваскулярных событий у пациентов с ишемической болезнью сердца и ожирением
RU2245556C2 (ru) Способ диагностики воспаления в дебюте ревматоидного артрита
Низаметдинова et al. The study of lipid spectrum and markers of vascular inflammation in patients with stable angina pectoris with diabetes mellitus
RU2734671C1 (ru) Способ прогнозирования риска прогрессирования хронической сердечной недостаточности у пациентов с перенесенным инфарктом миокарда
John et al. Acute Cardiac Manifestations of SARS-CoV-2 Infection: Spotting the Clot.
Kovačević et al. A fatal case of fulminant myocarditis caused by influenza A virus
Kerley et al. Case Report Acute Cardiac Manifestations of SARS-CoV-2 Infection: Spotting the Clot
RU2691620C1 (ru) Способ прогнозирования риска развития ишемической болезни сердца у пациентов с сахарным диабетом 2 типа в сочетании с субклиническим тиреотоксикозом
Milicic et al. Sodium and potassium intake in rural population
Kamasova et al. ADHERENCE TO ANTIHYPERTENSIVE MEDICATION AND LEFT VENTRICULAR HYPERTROPHY IN RESISTANT ARTERIAL HYPERTENSION
Bondar et al. NGS and NanoString Platforms Play Complementary Role in Bedside Advanced Heart Failure Outcome Prediction Test Development
Kamilova CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF STABLE ANGINA PECTORIS IN ELDERLY WOMEN WITH CONCOMITANT ARTERIAL HYPERTENSION
CEOBANU et al. Viral Myocarditis: Clinical and Paraclinical Diagnosis
Seki et al. ASSOCIATION OF URINARY SALT EXCRETION WITH BLOOD PRESSURE AND CLINICAL PARAMETERS IN TREATED AND UNTREATED ESSENTIAL HYPERTENSION
Branco et al. P2623 Combined aortic valve replacement and coronary artery bypass grafting: the impact of incomplete revascularization in long term survival
Andre et al. Session held on 8 July 2016